Pricing Log in Create free account
Saturday 17 October 2026 Export RGNX’s income statement to Excel — free account

REGENXBIO Inc.

RGNX Healthcare Biotechnology

REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024. In the quarter to June 2026, revenue grew 405.7%, EPS grew 131.2% and free cash flow fell 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.93 0.23 −3.21%
Market cap
$472.7M
P/E
0.0×
Fwd P/E
−2.2×
Dividend yield
—
F-score
5/9
Altman Z
−2.57
Beneish M
−2.77
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.95
Total sells 0.94
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 1 — —
Sell — — — — 1 — 1 1 1 — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 472.65
Revenue 174.48
Net Income (196.43)
Free Cash Flow (249.67)
Net Debt (105.74)
Current Ratio 2.86 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (2.20) (negative: loss-making)
P/S ratio 2.10
P/B ratio 5.10
Past 5Y EPS Growth —
This Y EPS Growth 10.54%
Next Y EPS Growth 13.81%
Next Y revenue growth (3.96%) (below 0%: weak)
Next 5Y EPS Growth 26.41% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.5×, against a ten-year median of 6.2×; over the ten years it ranged from −0.4× in 2016 to 96.0× in 2017.
P/S against its own 10 years 3.46%
10-year low 10-year high
P/B against its own 10 years 89.50%
10-year low 10-year high
EV/Sales against its own 10 years 12.92%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 275 235 230 106
Receivables 25 20 26 107
Inventory — — — —
Other 20 14 13 12
335 278 281 236
2023 2024 2025 Q'26
Payables 23 23 21 16
ST’ Debt — — — —
Other 51 34 40 27
130 103 118 83

Compound Annual Growth %

10y 5y 3y
Sales 36.50% 1.97% 14.78%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (7.20%) (22.93%) (41.62%)

Revenue $m

Mar Jun Sep Dec Year
’26 6 108 — — —
’25 89 21 30 30 170
’24 16 22 24 21 83
’23 19 20 29 22 90
’22 22 33 27 31 113
’21 19 22 31 399 470
’20 18 17 99 21 155
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (76) (62) — — —
’25 34 (49) (56) (52) (124)
’24 (55) (45) (41) (32) (173)
’23 (81) (47) (49) (41) (218)
’22 (56) (62) (50) (39) (207)
’21 (44) (36) (43) 341 219
’20 (36) (21) (36) 39 (54)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (77) (63) — — —
’25 33 (50) (56) (53) (126)
’24 (56) (46) (41) (33) (176)
’23 (86) (50) (51) (42) (228)
’22 (67) (71) (56) (45) (238)
’21 (75) (56) (61) 327 135
’20 (40) (25) (43) 27 (81)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (1.72) 0.43 — — —
’25 0.12 (1.38) (1.20) (1.30) (3.76)
’24 (1.38) (1.05) (1.17) (1.01) (4.59)
’23 (1.53) (1.66) (1.41) (1.43) (6.02)
’22 (1.79) (1.58) (1.75) (1.38) (6.50)
’21 (1.20) (1.36) (1.37) 6.67 2.91
’20 (1.08) (0.91) 0.23 (1.24) (2.98)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 7.07 16.30 23.25 30.38 20.03 27.02 18.69 12.82 7.14 5.04

Analyst estimates 2026–2028

Powerpack
High 24.55 36.10 85.10 63.21 54.97 50.26 35.73 25.54 28.80 15.41
People
People Employees 107 139 192 257 306 372 401 344 353 371
Revenue/emp, $m 0.04 0.07 1.14 0.14 0.51 1.26 0.28 0.26 0.24 0.46
Income, $m
Income, $m Revenue 5 10 219 35 155 470 113 90 83 170
Gross margin, % 79.10 83.56 95.59 76.61 76.89 88.98 51.61 58.76 59.72 88.09
EBT (63) (73) 104 (97) (106) 141 (280) (264) (227) (194)
EBT margin, % (1,381.61) (704.02) 47.65 (276.70) (68.59) 30.03 (248.75) (292.15) (272.54) (113.75)
Net income (63) (73) 100 (95) (111) 128 (280) (263) (227) (194)
Depreciation 3 5 5 6 9 15 18 18 16 16
Per share, $
Per share, $ Revenue 0.17 0.35 6.54 0.96 4.15 11.08 2.61 2.06 1.68 3.30
Earnings (2.38) (2.45) 2.99 (2.58) (2.98) 3.01 (6.50) (6.02) (4.59) (3.76)
Cash flow (1.84) (1.94) 3.13 (2.94) (1.45) 5.16 (4.81) (4.99) (3.50) (2.40)
Capex (0.31) (0.24) (0.40) (0.32) (0.72) (1.98) (0.71) (0.23) (0.05) (0.05)
Free cash flow (2.15) (2.18) 2.73 (3.25) (2.17) 3.17 (5.52) (5.22) (3.55) (2.45)
Book value 6.12 6.13 15.22 12.27 10.13 18.01 11.96 7.13 5.24 1.99
Shares, m 26 30 33 37 37 42 43 44 50 52
Valuation, ×
Valuation, × P/E 0.00 0.00 13.15 0.00 0.00 11.12 0.00 0.00 0.00 0.00
P/S 106.46 99.90 6.42 42.66 10.94 2.95 8.52 8.89 4.59 4.36
P/B 3.02 5.67 2.76 3.34 4.48 1.82 1.86 2.57 1.47 7.23
EV/Sales 86.95 84.43 4.98 34.42 7.90 1.99 5.33 5.90 1.85 3.04
EV/FCF (7.04) (13.47) 11.91 (10.16) (15.09) 6.95 (2.52) (2.33) (0.88) (4.10)
Cash, $m
Cash, $m Operating cash flow (49) (58) 105 (108) (54) 219 (207) (218) (173) (124)
Capex (8) (7) (13) (12) (27) (84) (31) (10) (2) (2)
Free cash flow (57) (65) 91 (119) (81) 135 (238) (228) (176) (126)
Balance, $m
Balance, $m Working capital 84 154 316 311 450 388 286 205 175 163
Total debt — — 6 9 70 85 89 — — —
Net debt (90) (161) (314) (296) (476) (457) (365) (275) (235) (230)
Shareholders’ equity 162 183 509 450 378 764 516 312 260 103
Returns, %
Returns, % ROA (31.95) (39.40) 26.92 (18.19) (18.45) 14.03 (28.79) (37.45) (43.68) (42.19)
ROIC (56.57) (213.15) 28.25 (60.48) 0.00 32.58 (108.41) (459.32) (584.21) 0.00
ROE (33.27) (42.45) 28.89 (19.76) (26.87) 22.39 (43.78) (63.65) (79.49) (107.00)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

REGENXBIO Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MNPR Monopar Therapeutics Inc. $481.9M — (loss-making) — — n/m −201.41% (below 0%: shrinking) — 0.00% Compare
ENTX Entera Bio Ltd. $481.5M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m −108.86% (below 0%: shrinking) 0.00% 0.00% Compare
NGNE Neurogene Inc. $479.3M — (loss-making) — (loss-making) — n/m −22.97% (below 0%: shrinking) 100.00% 0.00% Compare
YDES YD Bio Limited $477.5M — — — — — — — Compare
RGNX REGENXBIO Inc. $472.7M — (loss-making) — (loss-making) +405.73% (above 0%: growing) n/m −26.67% (below 0%: shrinking) 99.04% 27.09%
ARVN Arvinas, Inc. $468.2M 53.6× — (loss-making) +1,014.73% (above 0%: growing) n/m +49.79% (above 0%: growing) 96.40% 65.72% Compare
CBIO Crescent Biopharma, Inc. $463.6M — (loss-making) — (loss-making) +1,038,900.00% (above 0%: growing) n/m −7.04% (below 0%: shrinking) 100.00% 0.00% Compare
ALLO Allogene Therapeutics, Inc. $463.0M — (loss-making) — (loss-making) +20,990.91% (above 0%: growing) n/m +17.73% (above 0%: growing) 100.00% (1,011.21%) Compare
ALT Altimmune, Inc. $459.1M — (loss-making) — (loss-making) +520.00% (above 0%: growing) n/m −25.27% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $472.8M — — +1,014.73% — −22.97% 100.00% 0.00%

All 614 Biotechnology stocks →

REGENXBIO Inc. (RGNX) key facts

  • Concern: REGENXBIO Inc. reported a net loss of $193.9 million, or a loss of $3.76 per share, for fiscal 2025.
  • Strength: REGENXBIO Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.4 million, up 104.5% from fiscal 2024.
  • REGENXBIO Inc. (RGNX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, RGNX traded at $6.93, a market capitalization of $472.7 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.1× sales.
  • Return on equity was −107.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −2.57 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

REGENXBIO Inc. (RGNX) Latest News

14 May

Impact 5 ·
Impact 5 ·

6 May

Impact 5 ·
stockrow.com/RGNX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com